Ecosystem Over Geography: Life Sciences Location Strategy in APAC

Ecosystem Over Geography: Life Sciences Location Strategy in APAC

Life sciences companies in Asia-Pacific are shifting from traditional geographic clustering to ecosystem-based location strategies. This article analyzes the key factors driving this change and its implications for strategic planning. The Ecosystem Over Geography Life Sciences reorientation forces BD and strategy teams to weigh talent density, regulatory alignment, and innovation-network depth as heavily as tax holidays or facility costs—and the June 2024 analysis from JLL documents how this structural break is playing out across the region.

Key Takeaways

• Location decisions in APAC now pivot on ecosystem quality—innovation-cluster density, talent pipelines, and regulatory clarity—rather than geography or labor-cost arbitrage alone, per JLL's June 2024 report.
• Singapore delivers strategic advantages in IP protection and regulatory alignment with EMA standards, while China leads in pipeline growth and patent filings—but each market demands a distinct ecosystem calculus.
• Companies must conduct formal ecosystem audits for potential APAC sites, scoring talent availability, academic collaboration networks, and clinical trial infrastructure as core criteria alongside traditional real-estate metrics.

What's driving the ecosystem-over-geography shift?

JLL's report, authored by research managers Kaiwen Li and Kamya Miglani, documents that APAC life sciences companies now prioritize innovation clusters, talent density, and regulatory alignment over traditional cost-based decisions. The report explicitly labels this an "ecosystem over geography" approach—a framing that signals a deliberate departure from the manufacturing-cost arbitrage model that dominated the region for decades. That model tended to treat APAC as a production floor rather than a research partner, and the JLL analysis suggests that mindset is giving way to one that values translational infrastructure and policy coherence.

Asia now leads global biopharma pipeline growth and patent filings, according to McKinsey, with China and Singapore as primary beneficiaries. Those pipeline numbers reflect sustained government R&D spending and the deliberate build-out of translational research networks—exactly the kind of ecosystem assets that anchor discovery labs, clinical operations, and strategic partnerships. Demographic tailwinds reinforce the trend: aging populations, rising chronic-disease burdens, and an expanding middle class are pushing sector growth rates above those of mature Western markets, giving APAC governments both incentive and budget to invest in biomedical infrastructure. The JLL report cites these tailwinds directly as a macro factor accelerating ecosystem formation across the region.

How should pharma teams adapt their location strategy?

For BD and corporate strategy teams, the ecosystem-over-geography shift means location strategy must integrate directly with R&D and commercial planning—it can no longer be a standalone real-estate exercise. Proximity to top research universities, density of clinical trial infrastructure, and the clarity of regulatory pathways are now the decisive variables. Companies that treat site selection as a pure cost-minimization problem risk anchoring themselves in markets with weak translational pipelines or opaque regulatory routes.

Singapore's regulatory alignment with the EMA gives it a distinct gateway advantage for firms targeting both Asian and Western markets from a single hub. But the calculus extends beyond the city-state. The JLL analysis points to a widening gap between hubs that invest in ecosystem depth—talent development, IP protection, translational funding—and those that rely on baseline cost advantages. Teams should conduct formal ecosystem audits for each candidate site, scoring talent availability, collaboration-network density, and IP enforcement track records alongside traditional real-estate metrics. That audit should be refreshed annually as government biomedical budgets shift and as new academic partnerships emerge, because the half-life of an ecosystem advantage in APAC is shortening with each new research cluster that comes online.

The shift also opens room for second-tier hubs that offer specialized rather than general strengths. While the JLL report does not single out specific markets for advanced-therapy manufacturing or clinical trial efficiency, the ecosystem logic implies that any market investing in dedicated translational infrastructure—cell and gene therapy cleanrooms, phase I trial units, regulatory fast-track pathways—can compete for specific asset types even without the scale of a Shanghai or Singapore.

Frequently Asked Questions

Related coverage

• Illumina's APAC Strategy Under Nilesh Shah: A Competitive Benchmark
• AI Tools Transforming Clinical Trials in Life Sciences
• Poly Medicure appoints Indranil Mukherjee as CEO, APAC & India: Strategic implications for pharma BD teams